Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Were you diagnosed with diabetes before taking Tequin?

Were you diagnosed with diabetes after taking Tequin?

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Tequin associated with hypoglycemia and hyperglycemia

Apr 17, 2006 |

The FDA ( U.S. Food and Drug Administration ) has changed labeling for Tequin ( Gatifloxacin ), an antibiotic indicated for the treatment of patients with pneumonia, bronchitis, uncomplicated gonorrhea, and various infections including infections of urinary tract, kidneys, and skin.

The labeling changes update the prescription information as a result of continued reports of serious cases of hypoglycemia and hyperglycemia in patients receiving Tequin.

Since the approval of Tequin in 1999, there have been rare cases of life-threatening events reported globally in patients treated with the drug. Most of these events were reversible when properly managed, but a few had fatal outcomes.

Prescribing information has been revised to include a Contraindication in diabetic patients due to serious reports of hypoglycemia and hyperglycemia ( dysglycemia ).

Additionally, the Warnings and Precautions sections have been updated to identify other risk factors for dysglycemia ( older age, renal insufficiency, concomitant glucose-altering medications ) while taking Tequin, and include a recommendation for close medical monitoring.

Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo